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1,2 The cause of this rise is unclear. Importantly, however, SBP does not seem to rise with age in all societies, thus suggesting that rising SBP with age is not an inevitable part of aging but rather may be preventable. 2 Indeed, several studies have reported that persons with higher baseline SBP seem to experience a faster rate of rise in SBP over time as compared with persons with lower levels of SBP. [1] [2] [3] This observation has led to the hypothesis that increased SBP causes vascular injury or dysfunction, which in turn leads to higher SBP and a cycle of accumulating vascular injury that manifests as increasing SBP with age. 3 This hypothesis has potentially important clinical implications because if increased SBP causes blood pressure to rise with age, then lowering SBP beginning before the development of hypertension may prevent or slow the usual age-related rise in SBP.
We sought to evaluate whether SBP has a causal effect on the rate of rise in SBP with age by appealing to the principle of Mendelian randomization. Multiple polymorphisms are associated with SBP, 4 and each of these polymorphisms is allocated approximately randomly at the time of conception in a process referred to as Mendelian randomization. 5 Therefore, evaluating the effect of higher or lower SBP mediated by these polymorphisms should provide a naturally randomized and therefore unconfounded estimate of the causal effect of SBP on the usual age-related rise in SBP. Specifically, if SBP is causally related to the rate of rise in SBP with age, then polymorphisms associated with lower SBP should also be independently associated with a slower rise in SBP over time. By contrast, if SBP is not in this causal pathway, then naturally random allocation to higher or lower SBP mediated by genetic polymorphisms should not have any effect on the observed rate of rise in SBP over time.
We therefore tested the hypothesis that SBP is causally associated with age-related rise in SBP by evaluating the association between lower SBP mediated by a variety of different genetic polymorphisms and the rate of rise in SBP over time. In addition, we constructed genetic SBP scores to estimate the magnitude of the clinical effect of exposure to lower SBP beginning before the development of hypertension on both the usual rate of rise in SBP over time and the risk of coronary heart disease (CHD).
Methods
To begin, we searched PubMed, Embase, and Index of Science, as well as the supplementary materials, online data repositories, and references of selected articles, to identify individual studies that reported the association between SBP and ≥1 of the 26 single-nucleotide polymorphisms (SNPs) that were associated with SBP at genome-wide level of significance in the International Consortium for Blood Pressure Genome-Wide Association Studies (ICBP). 4 For each polymorphism, we defined the exposure allele as the allele associated with lower SBP.
To test the hypothesis that SBP is causally associated with the rise in SBP with age, we performed a meta-regression analysis measuring the effect modification of age on the association between each exposure allele and SBP, respectively. Because of the conceptual and numeric equivalence between a regression term in a meta-regression model and an interaction term in a general linear model, and because a single interaction term defines the effect modification between any 2 exposure variables, this analysis provides both an estimate of the change in the effect of an exposure allele on SBP with increasing age and an estimate of the difference in the age-related rise in SBP per copy of the exposure allele. 6 We then combined the β-coefficients representing the difference in age-related rise in SBP per copy of the exposure allele for each SNP in a meta-analysis to produce a summary estimate of the effect of lower SBP on the rise in SBP over time.
Next, we looked up the reported effect of each exposure allele on the change in SBP over time (defined as the difference in SBP measured at baseline and after re-examination a mean of 23 years later) among participants in the Malmo Preventive Project (MPP). 7 We then combined these effect estimates in a meta-analysis to estimate the effect of lower SBP mediated by the combined effect of these polymorphisms on the rate of rise in SBP over time and compared it with the results of the meta-regression analyses.
To estimate the magnitude of the effect of each mm Hg lower SBP on the rate of rise in SBP over time, we standardized the effect of each exposure allele by dividing its effect on the age-related rate of rise in SBP (and the corresponding standard error) by the effect of that SNP on SBP measured in mm Hg at 40 years of age (with this effect estimate derived by centering the meta-regression analysis around 40 years of age). We then created a genetic SBP score by combining these weighted effect estimates in a meta-analysis to obtain a summary estimate of the magnitude of the effect of naturally random allocation to each mm Hg lower SBP on the age-related rise in SBP. 8 To estimate the effect of lifelong exposure to lower SBP on the risk of CHD mediated by these polymorphisms, we looked up the effect of each exposure allele on the risk of CHD, as reported among ≤22 223 case and 64 762 control subjects in the Coronary ARtery DIsease Genome-Wide Replication And Meta-Analysis (CARDIoGRAM) consortium, 9 and divided this effect estimate (and its standard error) by the effect of that exposure allele on SBP as reported in the ICBP. 4 We then created a genetic SBP score by combining these weighted effect estimates in a meta-analysis to obtain a summary estimate of the magnitude of the effect of each mm Hg lower SBP on the risk of CHD. We compared the magnitude of the effect of genetically mediated lifelong exposure to lower SBP on the risk of CHD with the magnitude of the effect observed per mm Hg lower SBP in a meta-analysis of prospective epidemiological cohort studies 10 and in an updated metaanalysis of hypertension treatment randomized controlled trials conducted among persons without a history of cardiovascular disease.
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A detailed description of the methods is provided in the online-only Data Supplement. All meta-analyses and meta-regression analyses were performed using inverse-variance weighted random-effects models. All analyses used publically available summary data and therefore inherited all adjustments made in the original analyses (including adding either 10 or 15 mm Hg to the measured SBP among persons being treated with blood pressure-lowering medications). Effect estimates were compared using a Z test. All statistical tests used a 2-sided α <0.05 as the threshold for nominal statistical significance, and all analyses were performed using STATA (version 12).
Results
Sufficient data to permit detailed meta-regression analyses were available for 12 of the 26 polymorphisms associated with SBP in the ICBP (Table S1 in the online-only Data Supplement). In separate meta-regression analyses involving ≤23 studies and 163 674 participants, the exposure allele for all 12 polymorphisms was associated with both a lower SBP (Table) and a slower rate of rise in SBP over time ( Figure 1) . 4, [12] [13] [14] [15] [16] [17] Overall, the weighted mean effect of these 12 polymorphisms was associated with a 0.31-mm Hg lower SBP (95% confidence interval [CI], 0.15-0.48; P=1.34×10 −4 ) at a mean age of 43.2 years and a 0.092-mm Hg/decade slower rise in SBP with age (95% CI, 0.045-0.139; P=6.26×10 −4 ). The effect of 11 of these 12 polymorphisms on the change in SBP over time was also evaluated in the MPP. 7 Among 11 290 persons enrolled in MPP without hypertension at baseline, the weighted mean effect of these 11 exposure alleles was associated with a 0.32-mm Hg lower SBP (95% CI, 0.14-0.49; 
P=3.7×10
−4
) at a mean age of 45.6 years and a 0.094-mm Hg/ decade slower rise in SBP over time (95% CI, 0.017-0.171; P=0.017; Table S2, Figure 2 ). This estimate of the effect of exposure to lower SBP on the rate of rise in SBP with age among participants enrolled in MPP agreed closely with the results of the meta-regression analyses ( Figure 3) . In an analysis that combined data from the meta-regression analyses and the MPP, the weighted mean effect of these exposure alleles was associated with a 0.32-mm Hg lower SBP (95% CI, 0.20-0.43; P=1.79×10 −7 ) and a 0.093-mm Hg/decade slower rise in SBP with age (95% CI, 0.05-0.13; P=3.05×10 −5 ). Using a weighted genetic SBP score composed of all 12 polymorphisms and data from the meta-regression analyses, naturally random allocation to each mm Hg lower SBP was associated with a 0.324-mm Hg/decade slower rise in SBP (95% CI, 0.162-0.486; P=9.32×10 −4 ; Table S3 ). This effect estimate agreed closely with the 0.349-mm Hg/decade slower rise in SBP per mm Hg lower SBP observed in the MPP (95% CI, 0.205-0.492; P=1.59×10 −6 ), estimated using a genetic SBP score composed of 29 polymorphisms associated with either SBP or diastolic blood pressure. 7 To further explore the effect of exposure to lower SBP on the rate of rise in SBP with age, we plotted the effect of 10 polymorphisms on SBP, where the effect of each polymorphism was measured at multiple different common points in time. 7, 17 The absolute weighted mean effect of these polymorphisms on SBP increased approximately linearly over time from 10 to 63 years of age ( Figure 4 ) by 0.072 mm Hg/decade ). The slope of this regression line represents both an estimate of the change in the mean effect of these polymorphisms on SBP with increasing age and the difference in the age-related rate of rise in SBP attributable to the effect of lower SBP mediated by these polymorphisms, because these 2 estimates of effect modification are numerically equivalent. Therefore, this analysis also provides evidence that lower SBP is associated with a slower rise in SBP with age.
Using a separate weighted genetic SBP score composed of the same 12 polymorphisms, naturally random allocation to lifetime exposure to each mm Hg lower SBP was associated with a 6.1% lower odds of CHD (odds ratio, 0.94; 95% CI, 0.91-0.97; P=3.85×10 −4 ), whereas 5-mm Hg lower SBP was associated with a 27.0% (odds ratio, 0.73; 95% CI, 0.61-0.87; P=3.85×10 −4 ) lower odds of CHD, and 10-mm Hg lower SBP was associated with a 46.7% (odds ratio, 0.53; 95% CI, 0.38-0.75; P=3.85×10 −4 ) lower odds of CHD among participants in the CARDIoGRAM studies ( Figure 5A , Table S4a ). This effect estimate was essentially unchanged when measured using a genetic SBP score consisting of 25 of the 26 SNPs associated with SBP in the ICBP that were measured in the CARDIoGRAM studies ( Figure 5A , Table S4b ). 9 The magnitude of the effect of lifetime exposure to lower SBP observed in the genetic studies was >2-fold greater (on the log scale) per mm Hg than the magnitude of the effect observed in a meta-analysis of 61 prospective cohort studies involving almost 1 million persons (P difference=0.006) 10 and ≈3-fold greater (on the log scale) per mm Hg lower SBP than that observed in a meta-analysis of 27 hypertension treatment randomized controlled trials involving 109 792 participants without a prior history of cardiovascular disease (P difference= 0.001; Tables S5 and S6) . 11 A plot of the proportional risk reduction against the mean length of follow-up in these 3 analyses suggested an approximately log-linear relationship between the total length of exposure to lower SBP and the reduced risk of CHD ( Figure 5B ).
Discussion
We tested the hypothesis that SBP is causally related to the rise in SBP with age by evaluating the association between lower SBP mediated by a variety of genetic polymorphisms and the average rate of rise in SBP over time. Because genetic polymorphisms are allocated approximately randomly at the time of conception, these associations should provide an unconfounded estimate of the effect of exposure to lower SBP on the usual rise in SBP with age in a manner analogous to a long-term natural randomized trial. 8 We found that naturally random allocation to lower SBP mediated by multiple different common polymorphisms was associated with a significantly slower rise in SBP with age and a much larger reduction in the risk of CHD per mm Hg lower SBP than that observed in either prospective epidemiological cohort studies or short-term blood pressure-lowering randomized trials. We conclude therefore that SBP seems to be causally associated with the rate of rise in SBP with age and has a cumulative effect on the risk of CHD.
Multiple different lines of evidence in our study support the notion that SBP is causally associated with the rate of rise in SBP. The results of our study thus strongly support the hypothesis that increased SBP causes vascular injury, which in turn leads to higher SBP and a cycle of accumulating vascular injury that leads to increasing SBP over time. The direct implication of this finding is that lowering SBP beginning soon after it begins to rise with age and before the development of hypertension may potentially interrupt the cycle of accumulating vascular injury that appears to at least in part cause increasing SBP over time and thereby prevent or slow the usual age-related rise in SBP.
It is important to note, however, that we evaluated the effect of genetically mediated lifelong exposure to lower SBP. It is not known whether lowering SBP with diet, exercise, weight loss, or medications will have the same effect as genetically mediated lower SBP. Further studies are needed to determine whether lowering SBP beginning soon after it begins to rise with age and before significant vascular injury has developed can prevent or slow the usual age-related rise in SBP.
Preventing or slowing the usual rise in SBP with age may be a particularly important public health goal because SBP seems to have a cumulative effect on the risk of CHD. We found that lifetime exposure to each mm Hg lower SBP was associated with a 2-fold greater reduction in the risk of CHD than that observed in a meta-analysis of prospective cohort studies (corrected for regression dilution bias) 10 and a 3-fold greater effect than that observed in a meta-analysis of randomized trials comparing blood pressure-lowering treatment with placebo (or usual care) among persons with established hypertension. 11 The substantial and graded difference in the risk of CHD associated with lifetime exposure to lower SBP assessed in the genetic studies, medium-term exposure to lower SBP assessed in the epidemiological cohort studies, and short-term exposure to lower SBP assessed in the randomized trials suggests that the effect of SBP on the risk of CHD is not a threshold effect, but rather is cumulative. This finding may explain the observation that antecedent blood pressure is independently associated with the risk of CHD even after adjusting for current blood pressure in multiple different observational epidemiological studies. 18, 19 It may also explain the legacy effect observed in blood pressure-lowering trials in which the clinical benefit observed during the trial persists for several years after the trial was completed.
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The results of our study have important implications for interpreting other blood pressure genetic studies. We found that the absolute magnitude of the measured effect of polymorphisms associated with SBP appear to increase over time (Figure 4) . The apparently increasing effect of genetic polymorphisms on SBP over time can be explained by the fact that SBP is causally associated with the age-related rise in SBP. Therefore, the effect of a polymorphism associated with SBP, measured at any point in time, will actually be a composite of the effect of that polymorphism on SBP plus the additional effect that accrues over time because of the effect of SBP mediated by that polymorphism on the rate of rise in SBP over time. As a result, estimating the effect of SBP on the rate of rise in SBP with age, the odds of CHD, or any other outcome using a genetic score that adjusts the effect of each exposure allele by its effect on SBP measured in middle age will systematically underestimate the true magnitude of the effect of SBP on the outcome under study.
Our study has several limitations, including inherent limitations when making causal inferences using the principle of Mendelian randomization. 21 To address these limitations, we limited our analyses to SNPs that were reported to be associated with SBP at genome-wide level of significance in the ICBP. 4 Some of these polymorphisms, however, have been reported to have pleiotropic effects in addition to their effect on SBP. 4 We therefore based our conclusions on the weighted mean effect of these polymorphisms using a genetic SBP score. Because an SBP genetic score measures the effect of naturally random allocation to each unit lower SBP mediated by the combined effect of the SNPs included in the score, the results of our study should reflect the effect of lower SBP itself rather than the effect of any particular polymorphism or pathway. Including multiple polymorphisms each of which presumably acts through a different mechanism to lower SBP significantly reduces the likelihood that the analysis will be confounded by pleiotropy because it is unlikely that each of the SNPs included in the genetic SBP score acts through similar and directionally consistent pleiotropic effects. However, the Mendelian randomization paradigm does not allow us to exclude the possibility that each of the included SNPs is associated with ≥1 broad functional pathways such as inflammation that may independently influence both SBP and the rate of rise in SBP with age. Further study is needed to elucidate the mechanisms by which SBP seems to influence the rate of rise in SBP over time.
Perspective
We found that SBP seems to be causally associated with the rate of rise in SBP with age and has a cumulative effect on the risk of CHD. Therefore, the results of our study suggest that lowering SBP beginning soon after it begins to rise with age and before the development of hypertension may have the potential to significantly slow the usual age-related rise in SBP and substantially reduce the lifetime risk of CHD. What Is New?
• Using naturally randomized evidence, we show for the first time that systolic blood pressure (SBP) seems to be causally associated with the rate of rise in SBP with age and has a cumulative effect on the risk of coronary heart disease.
What Is Relevant?
• The finding that exposure to lower SBP beginning before the development of hypertension is associated with a slower age-related rise in SBP suggests that lowering SBP beginning before the development of hypertension may prevent or slow the usual age-related rise in SBP.
• The finding that SBP seems to have a cumulative effect on the risk of coronary heart disease suggests that preventing or slowing the usual age-related rise in SBP has the potential to substantially reduce the lifetime risk of coronary heart disease. 
I. Genetic meta-regression analyses
To assess the effect of naturally random allocation to lower SBP on the usual age-related rate of rise in SBP over time, we conducted a series of meta-regression analyses measuring the effect modification of age on the association between each exposure allele and SBP, respectively, by fitting the following meta-regression equation:
ES SNP-SBP = constant + ß 1 (Age) [1] where ES SNP-SBP is the effect size of the association between the exposure allele and SBP measured in mmHg, and Age is the mean baseline age of the participants in each study contributing to the analysis, measured in decades of time. These analyses inherit the multivariable adjustments made in the analysis of the association between the exposure allele and SBP made in the individual studies, including adjustments for age. In this equation, the constant term is the effect of SNP on SBP when Age=40 years, i.e. obtained by centering the meta-regression around the age 40 years by subtracting 40 from the mean age of each study. The null hypothesis is that the association between exposure allele and SBP is constant, and does not change over time (i.e. ß 1 = 0).
We note that the regression term in a meta-regression equation and an interaction term in a general (or generalized) linear model are conceptually and numerically identical measures of effect modification 13 . We further note that in a general linear model, a single interaction term defines the effect modification between any two exposure variables, as shown in the following equation: SBP = constant + ß 1 (Age) + ß 2 (SNP) + ß 3 (Age*SNP) [2] where ß 1 is the effect of Age on SBP among SNP non-carriers (i.e. when SNP = 0), and ß 2 is the per allele effect of SNP on SBP at the average Age of the population under study. The interaction term ß 3 is simultaneously a measure of both a) the effect modification of Age on the association between SNP and SBP, i.e. the amount that the effect of SNP on SBP changes over time (with Age); and b) the effect modification of SNP on the association between Age and SBP, i.e. the difference in the effect of Age on SBP among SNP carriers and non-carriers (per copy of the exposure allele).
Therefore, because a single interaction term defines the effect modification between any two epidemiologic exposures in a general linear model, and because the interaction term in a general linear model is conceptually and numerically equivalent to a regression term in a meta-regression equation, it follows that the effect modification of Age on the association between SNP and SBP (ß 1 ) measured in the following meta-regression equation:
ES SNP-SBP = constant + ß 1 (Age) [1] 3 must be exactly the same as the effect modification of Age on the association between SNP and SBP (ß 3 ) measured in the following general linear model: SBP = constant + ß 1 (Age) + ß 2 (SNP) + ß 3 (Age*SNP) [2] which, in turn, must be exactly the same as the effect modification of SNP on the association between Age and SBP (ß 2 ) measured in the following meta-regression equation:
ES AGE-SBP = constant + ß 1 ' (SNP). [3] That is, ß 1 in equation [1] must be equal to ß 3 in in equation [2] which must be equal to ß 1 ' in equation [3] . Thus ß 1 (effect modification of Age on the association between SNP and SBP) in equation [1] must be equal ß 1 ' (effect modification of SNP on the association between Age and SBP) in equation [3] .
Therefore, our estimate of the effect modification of Age on the association between each exposure allele (SNP) and SBP is also simultaneously an estimate of the effect modification of the exposure allele on the association between Age and SBP, because these two estimates of effect modification are identical. Finally, we note that the effect modification of SNP on the association between Age and SBP can be interpreted as an estimate of the difference in the usual age-related rate of rise in SBP over time due to naturally random allocation to lower SBP mediated by each copy of the exposure allele under study.
We performed separate meta-regression analyses for each SNP. We then standardized the estimate of the effect modification of Age on the association between each SNP and SBP per mmHg lower baseline exposure to lower SBP by dividing the beta term (and its standard error) by the constant term (effect of exposure allele on SBP at age 40 years), using the usual ratio of effect estimates method. This method standardizes the effect of each exposure allele on the rate of rise in SBP over time by the effect of that exposure allele on SBP measured in mmHg (ie. Per mmHg lower SBP).
Finally, we combined the effect modification estimates for each SNP weighted per mmHg lower SBP in an inverse variance-weighted random-effects meta-analysis. The result of this meta-analysis provides a summary estimate of the change in the association between each exposure allele and SBP per decade of increasing age, standardized per mmHg lower SBP. It is also an estimate of the difference in the rate of rise in SBP per decade among SNP carriers and non-carriers (per copy of the exposure allele), standardized per mmHg lower SBP. Therefore, the result of this meta-analysis represents a summary estimate of the effect of naturally random allocation to each unit lower SBP on the usual age-related rate of rise in SBP over time.
II. Calculation of the genetic SBP score
The statistical power of Mendelian randomization analyses can be increased by evaluating the combined effect of multiple genetic variants as instruments using a genetic score 14 . As has been previously demonstrated, for a set of genetic markers with small effect size and in linkage disequilibrium with each other, regression on a genetic risk score can be reconstructed from regressions on the individual SNPs without further access to individual-level data 1 . This is accomplished by weighting the association 4 between each exposure allele and the risk of the outcome of interest by the effect size of the exposure allele on the modifiable exposure of interest, and then combining these weighted effect estimates to produce an overall weighted summary estimate of effect.
To evaluate the effect of naturally random allocation to lower SBP on the risk of CHD, we constructed a genetic SBP score including up to 26 polymorphisms as follows. We first looked-up the association between the exposure allele for each SNP included in the SBP score and the risk of CHD in CARDIoGRAM studies 9 . We then weighted the effect of each exposure allele on the risk of CHD by dividing the natural log of the effect estimate for the association between that exposure allele and CHD (and its standard error) by the effect of that exposure allele on SBP, measured in mmHg, estimated from published data reported by the International Consortium of Blood Pressure Genome-Wide Association Studies 1 , using the usual ratio of effect estimates method. We then combined these weighted effect estimates in an inverse variance-weighted random-effects meta-analysis to produce an overall summary estimate of the effect of each mmHg lower SBP (mediated by the combined effect of the SNPs included in the genetic score) on the risk of CHD (Table S6a and S6b). 
